MedDay Provides Update on MS-ON Study of MD-1003
Second placebo controlled study with MD1003 in Multiple Sclerosis patients
Focus on patients with chronic visual loss following optic neuritis (ON)
Progressive ON sub-group analysis results consistent with ongoing MS-SPI trial and support potential of MD-1003 in the most difficult to treat Progressive Multiple Sclerosis patients
Latest results confirm the very good safety profile of MD1003
Source : http://www.businesswire.com/news/hom...-Study-MD-1003
Second placebo controlled study with MD1003 in Multiple Sclerosis patients
Focus on patients with chronic visual loss following optic neuritis (ON)
Progressive ON sub-group analysis results consistent with ongoing MS-SPI trial and support potential of MD-1003 in the most difficult to treat Progressive Multiple Sclerosis patients
Latest results confirm the very good safety profile of MD1003
Source : http://www.businesswire.com/news/hom...-Study-MD-1003
Comment